These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 15007103)

  • 21. Neurobin/TMPRSS11c, a novel type II transmembrane serine protease that cleaves fibroblast growth factor-2 in vitro.
    Stallmach R; Gloor SM
    Biochem J; 2008 May; 412(1):81-91. PubMed ID: 18215125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of urotensin II in human pathophysiology].
    Piech J; Skoczylas A
    Wiad Lek; 2008; 61(10-12):277-82. PubMed ID: 19323069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
    Chatenet D; Dubessy C; Boularan C; Scalbert E; Pfeiffer B; Renard P; Lihrmann I; Pacaud P; Tonon MC; Vaudry H; Leprince J
    J Med Chem; 2006 Nov; 49(24):7234-8. PubMed ID: 17125276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide.
    Watanabe T; Takahashi K; Kanome T; Hongo S; Miyazaki A; Koba S; Katagiri T; Pakara R; Benedict CR
    Hypertens Res; 2006 Oct; 29(10):821-31. PubMed ID: 17283870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible pathogenic link between migraine and urotensin-II.
    Bicak U; Karabiber H; Ozerol HI; Aslan M; Ilhan A; Yakinci C
    J Child Neurol; 2008 Nov; 23(11):1249-53. PubMed ID: 18984832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?
    Balat O; Aksoy F; Kutlar I; Ugur MG; Iyikosker H; Balat A; Anarat R
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):33-8. PubMed ID: 15866083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation.
    Basak A; Lotfipour F
    FEBS Lett; 2005 Aug; 579(21):4813-21. PubMed ID: 16102752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.
    Gagliardo B; Kubat N; Faye A; Jaouen M; Durel B; Deschemin JC; Canonne-Hergaux F; Sari MA; Vaulont S
    J Hepatol; 2009 Feb; 50(2):394-401. PubMed ID: 19070914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urotensin-II receptor peptide agonists.
    Carotenuto A; Grieco P; Novellino E; Rovero P
    Med Res Rev; 2004 Sep; 24(5):577-88. PubMed ID: 15224381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.
    Russell FD; Meyers D; Galbraith AJ; Bett N; Toth I; Kearns P; Molenaar P
    Am J Physiol Heart Circ Physiol; 2003 Oct; 285(4):H1576-81. PubMed ID: 12791592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Production of primary cells cultures by a semi-industrial technic. II. Use of active trypsin solutions for effective cell yields].
    Beyer R; Kohler A; Rex M; Bendt R
    Acta Biol Med Ger; 1981; 40(6):801-9. PubMed ID: 7324709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme pacemakers. II. Conversion of trypsinogen to trypsin; separation of trypsin and inactivator by paper electrophoresis.
    HAKIM AA
    Enzymologia; 1959 Mar; 20(4):207-14. PubMed ID: 13639901
    [No Abstract]   [Full Text] [Related]  

  • 33. [Study by light diffusion of the effects of pH on the degree of polymerization of trypsin].
    GUINAND S
    C R Hebd Seances Acad Sci; 1957 Nov; 245(19):1672-4. PubMed ID: 13489916
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of pH and cations on the theramal denaturation of trypsin.
    CREWTHER WG
    Aust J Biol Sci; 1953 Nov; 6(4):597-616. PubMed ID: 13126039
    [No Abstract]   [Full Text] [Related]  

  • 35. The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.
    Castel H; Desrues L; Joubert JE; Tonon MC; Prézeau L; Chabbert M; Morin F; Gandolfo P
    Front Endocrinol (Lausanne); 2017; 8():76. PubMed ID: 28487672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urotensin II in cardiovascular regulation.
    Russell FD
    Vasc Health Risk Manag; 2008; 4(4):775-85. PubMed ID: 19065995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of urotensin II in cardiovascular and renal physiology and diseases.
    Zhu YC; Zhu YZ; Moore PK
    Br J Pharmacol; 2006 Aug; 148(7):884-901. PubMed ID: 16783414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro.
    Russell FD; Kearns P; Toth I; Molenaar P
    J Pharmacol Exp Ther; 2004 Jul; 310(1):209-14. PubMed ID: 15007103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.
    Russell FD; Molenaar P
    Cardiovasc Res; 2004 Sep; 63(4):673-81. PubMed ID: 15306223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural requirements for furin-induced cleavage and activation of Shiga toxin.
    Kurmanova A; Llorente A; Polesskaya A; Garred O; Olsnes S; Kozlov J; Sandvig K
    Biochem Biophys Res Commun; 2007 May; 357(1):144-9. PubMed ID: 17407762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.